August 8, 2024
“Warren Buffett sent shockwaves through the investing world over the weekend by slashing his big Apple stake by half, causing the tech stock to crater on Monday amid the intensifying global sell-off. Berkshire Hathaway disclosed in its earnings filing that its Apple… Continue Reading…
August 8, 2024
“High-performing shares of Alphabet, Amazon, Meta Platforms, Microsoft and Tesla fell as much as 12.2% in premarket trading. The losses in the Magnificent Seven stocks were set to wipe out nearly $1 trillion from the combined market value of the… Continue Reading…
August 8, 2024
“Stocks fell sharply on Monday, with the Dow Jones Industrial Average posting its worst day in nearly two years, as worries over the health of the U.S. economy sparked a global market sell-off. The Dow dropped 1,033.99 points, or 2.6%, to end at 38,703.27.… Continue Reading…
August 7, 2024
“Amazon shares closed down about 8.7% on Friday, a day after the company reported mixed second-quarter results and gave a forecast for the third quarter that fell short of Wall Street’s expectations. Revenue in the second quarter rose 10% from a year earlier… Continue Reading…
August 2, 2024
“…So what gives? Should investors be worried? In short, probably not. Stocks naturally retreat after big gains. It’s to be expected; in fact, it’s healthy. Yes, 18% is a lot, many stocks move less over the course of a year,… Continue Reading…
August 1, 2024
“Shares of global semiconductor firms rallied on Wednesday as they were boosted by some positive earnings in the sector and a report of potentially less severe U.S. export restrictions on China. AMD was among the big winners with shares up… Continue Reading…
August 1, 2024
“Twelve stocks in the S&P 500, including Walgreens Boots Alliance (WBA), Dexcom (DXCM) and Super Micro Computer (SMCI), have already crashed 40% or more from their 52-week highs, says an Investor’s Business Daily analysis of data from S&P Global Market Intelligence and MarketSurge. A 40% decline is… Continue Reading…
July 31, 2024
“…RegenXBio (RGNX) The first Goldman pick we’ll look at is RegenXBio, a gene therapy company specializing in single-dose treatments for severe diseases with few or no existing therapies…. Choi rates RGNX a Buy along with a $38 price target. This… Continue Reading…
July 30, 2024
“Shares of Dexcom tumbled almost 40% in extended trading Thursday after the diabetes management company reported disappointing revenue for the second quarter and offered weak guidance. Here’s how the company did: Dexcom’s revenue increased 15% from $871.3 million a year earlier, according to a… Continue Reading…
July 29, 2024
“…“To date, the broad financial stability implications of changes in retail equity investor characteristics and behaviors have been limited,” the Fed said. The central bank specifically assessed what happened to shares of AMC Entertainment and GameStop in January, noting that activity and… Continue Reading…
Recent Comments